

Dean L. Engelhardt, et al.

Serial No.: 08/486,069

Filed: June 7, 1995

Page 3 [Supplemental Amendment To Applicants' September 12, 2002
Amendment Under 37 C.F.R. §1.115 -- October 11, 2002]

KINDLY AMEND THIS APPLICATION AS FOLLOWS:

In The Claims:

Add new claims 1769-1775 as follows:

1769 (New) A process for determining the sequence of a nucleic acid of interest comprising the steps of:

(II) generating detectable non-radioactively labeled nucleic acid fragments complementary to said nucleic acid of interest or a portion thereof, wherein said fragments have been labeled by incorporation of one or more detectable non-radioactive modified or labeled nucleoside triphosphates or analogs thereof, said nucleoside triphosphates or analogs comprising fluorescent or chemiluminescent indicators;

subjecting said labeled fragments to a sequencing gel to separate or resolve said fragments; and

detecting each of said separated or resolved fragments by means of the fluorescent or chemiluminescent indicators, to determine the sequence of said nucleic acid of interest.

1770. (New) The process according to claim 1769, wherein in said generating step, said one or more detectable non-radioactive modified or labeled nucleoside triphosphates or analogs thereof comprise a sugar moiety or sugar analog.

Dean L. Engelhardt, et al.

Serial No.: 08/486,069

Filed: June 7, 1995

Page 4 [Supplemental Amendment To Applicants' September 12, 2002

Amendment Under 37 C.F.R. §1.115 -- October 11, 2002]

1771. (New) The process according to claim 1770, wherein said sugar moiety or sugar analog comprises a furanose selected from the group consisting of ribose, deoxyribose, dideoxyribose and analogs thereof.

1772. (New) The process according to claim 1769, wherein in said generating step, said one or more detectable non-radioactive modified or labeled nucleoside triphosphates or analogs thereof comprise a phosphate moiety or a phosphate analog.

1773. (New) The process according to claim 1769, wherein in said generating step, said one or more detectable non-radioactive modified or labeled nucleoside triphosphates or analogs thereof comprise a base moiety or a base analog.

1774. (New) The process according to claim 1773, wherein said base moiety or base analog comprises a purine, a purine analog, a pyrimidine, or a pyrimidine analog.

(II)
Concl
1775. (New) The process according to claim 1773, wherein the fluorescent or chemiluminescent indicators in said one or more detectable non-radioactive modified or labeled nucleoside triphosphates or analogs thereof are attached to said base moiety or said base analog.

* * * * *